Medical Electronic Nose segmentation by application delineates four primary use‑cases that collectively drive market revenue. Respiratory disease diagnosis—including asthma, COPD, and lung cancer screening—accounts for the largest share, reflecting the high prevalence of pulmonary conditions and the technology’s ability to detect volatile organic compounds (VOCs) in exhaled breath. This segment contributes roughly 40 % of total sales, supported by hospital procurement and reimbursement pathways. Oncology screening leverages the device’s sensitivity to tumor‑derived metabolites, enabling early detection of breast, colorectal, and pancreatic cancers; it represents an estimated 25 % of the market, propelled by clinical trial validation and rising demand for non‑invasive diagnostics. Infectious disease detection applies electronic noses to identify bacterial and viral pathogens through breath signatures, currently capturing about 20 % of revenue as healthcare systems adopt rapid screening for COVID‑19, tuberculosis, and sepsis. Finally, Metabolic disorder monitoring—primarily diabetes and renal disease—covers the remaining 15 %, driven by outpatient monitoring programs and integration with telehealth platforms. Together, these applications form the market taxonomy that underpins growth projections.